Thursday, September 07, 2017 3:00:19 PM
I think a hostile takeover is probably more likely. I guess it depends on how many share holders bought in at these levels, and how many are holding diluted shares from $5+?
I'm not ready to say BK is the option by any means, all I was saying is that it's an option that is on the table.
Selfishly, that is where I thrive. A BK announcement would drop the price to .05 or less. I'd then work my connections with the US Trustee and various attorneys I know to form an OEC (I've formed three in the last decade), and would try to force a market test.
Presuming offers come in closer to the market value for Chemosat, the creditors would be faced with two options:
1) Recoup their $15M plus interest
2) Negotiate a deal where they agree to extinguish the debt for some shares, but not enough to wipe out the company. Using the offers as a starting point with the assumption that upon FDA approval those shares will be worth a lot more.
But I don't think BK is likely. I give it only a 10% chance or so. And if it does happen, the odds of shareholders recovering less than what they could get right now for their shares (.13) is even lower.
I'm not ready to say BK is the option by any means, all I was saying is that it's an option that is on the table.
Selfishly, that is where I thrive. A BK announcement would drop the price to .05 or less. I'd then work my connections with the US Trustee and various attorneys I know to form an OEC (I've formed three in the last decade), and would try to force a market test.
Presuming offers come in closer to the market value for Chemosat, the creditors would be faced with two options:
1) Recoup their $15M plus interest
2) Negotiate a deal where they agree to extinguish the debt for some shares, but not enough to wipe out the company. Using the offers as a starting point with the assumption that upon FDA approval those shares will be worth a lot more.
But I don't think BK is likely. I give it only a 10% chance or so. And if it does happen, the odds of shareholders recovering less than what they could get right now for their shares (.13) is even lower.
Recent DCTH News
- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts • Business Wire • 05/26/2026 08:01:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
